威高血净1月19日获融资买入616.82万元，融资余额1.29亿元

Core Viewpoint - The company, Weigao Blood Purification, has shown a slight increase in stock price and has reported its financial activities, including financing and revenue growth, indicating a stable performance in the blood purification industry [1][2]. Financing Summary - On January 19, Weigao Blood Purification had a financing buy amount of 6.1682 million yuan, with a net financing buy of 78,900 yuan after repayments [1][2]. - The current financing balance stands at 129 million yuan, accounting for 7.96% of the circulating market value [2]. Stock and Shareholder Information - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, which is a decrease of 20.95% compared to the previous period [2]. - The average circulating shares per person increased by 26.51% to 1,535 shares [2]. Revenue and Profit Performance - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, reflecting a year-on-year growth of 3.45% [2]. - The net profit attributable to the parent company was 341 million yuan, representing a year-on-year increase of 7.92% [2]. Dividend Information - Weigao Blood Purification has cumulatively distributed dividends amounting to 65.8213 million yuan since its A-share listing [3].